SYNERGISTIC HEALING: EVALUATING PAROXETINE WITH PSYCHOTHERAPY IN PANIC ATTACK MANAGEMENT

Abstract

Paroxetine was the first selective serotonin reuptake inhibitor (SSRI) approved for the treatment of panic disorder, with or without agoraphobia. It acts as a highly selective inhibitor of presynaptic serotonin (5-HT) reuptake and shows minimal interaction with adrenergic, dopaminergic, histaminergic, or serotonergic receptors. Clinical trials have demonstrated that oral paroxetine, administered at doses of 10–60 mg/day, is significantly more effective than placebo in reducing the frequency of panic attacks and alleviating associated symptoms. Its therapeutic benefits were sustained for up to six months, with ongoing treatment reducing relapse risk. In comparative studies, paroxetine was found to be at least as effective as clomipramine (10–150 mg/day), with a more rapid onset of action in some cases. 

DOI - https://doi.org/10.65525/SVUP.9788199651555.2026.99-123